St Stephen's Research perform high quality, patient focused research into HIV and hepatitis infections, and other therapeutic areas, from 'first into man' to post marketing phase.
Based at the Chelsea & Westminster Hospital, the centre of excellence with one of the largest HIV patient cohorts in Europe, PKR and SSR offer an exemplary clinical environment for both patients and employees.
2006
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial
Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS. 2005 Jul 22;19(11):1183-8.
The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: appearances in 11 patients.
Rajeswaran G, Becker JL, Michailidis C, Pozniak AL, Padley SP. The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: appearances in 11 patients. Clin Radiol. 2006 Oct;61(10):833-43.
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Bethune MP, Peeters M, Woodfall B. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects. AIDS. 2006 Aug 22;20(13):1721-6.
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006 May;80(10):4909-20.
Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006 Jan 19;354(3):251-60.
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.
Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M; UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005 Dec 10;331(7529):1368. Epub 2005 Nov 18.
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005 Nov;11(11):1170-2. Epub 2005 Oct 5.
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial
Arasteh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E; TMC114-C207 Study Team. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS. 2005 Jun 10;19(9):943-7.
The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine
Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther. 2005;10(2):357-61.
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005 Mar 25;19(5):487-94.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide
Walmsley S, Henry K, Katlama C, Nelson M, Castagna A, Reynes J, Clotet B, Hui J, Salgo M, DeMasi R, Delehanty J. Related Articles, Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis. 2003 Dec 15;188(12):1827-33. Epub 2003 Dec 5.
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003 May 29;348(22):2186-95.
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD; MaxCmin2 Trial Group. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10(6):735-43.
Bone mineral abnormalities in persons with HIV infection: signal or noise?
Singh K, Moyle GJ. Bone mineral abnormalities in persons with HIV infection: signal or noise? AIDS Read. 2006 Aug;16(8):407-10, 413-8.
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen
Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B. Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med. 2006 May;7(4):243-7.
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy
Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, Fisher M, Gazzard B. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006;11(1):73-8.
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy
Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006 Apr;7(3):181-5.
The role of zidovudine in development of lipoatrophy
Moyle GJ. The role of zidovudine in development of lipoatrophy. AIDS Read. 2005 Nov;15(11):591-4, 599-600, 603.
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jarvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.
Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med. 2005 Nov;6(6):396-402.
Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
Moyle GJ. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir. AIDS Read. 2005 Oct;15(10):531.
A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV
Moyle G. A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV. Int J STD AIDS. 2005 Oct;16 Suppl 1:14-20; discussion 20-2, 41-3
Tenofovir and didanosine: a dangerous liaison
Waters L, Maitland D, Moyle GJ. Tenofovir and didanosine: a dangerous liaison. AIDS Read. 2005 Aug;15(8):403-6, 413
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother. 2006 Sep 19; [Epub ahead of print]
Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies.
Boffito M, Pillay D, Wilkins E. Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Int J Clin Pract. 2006 Sep;60(9):1098-106.
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses
Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses. 2006 Aug;22(8):749-56.
The clinical pharmacology of antiretrovirals in development
Winston A, Mallon PW, Boffito M. The clinical pharmacology of antiretrovirals in development. Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):447-58.
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006 Jun 26;20(10):1401-6.
The clinical implications of antiretroviral pharmacogenomics. Pharmacogenomics
Fox J, Boffito M, Winston A. The clinical implications of antiretroviral pharmacogenomics. Pharmacogenomics. 2006 Jun;7(4):587-96.
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response
Winston A, Patel N, Back D, Khoo S, Bulbeck S, Mandalia S, Pozniak AL, Nelson M, Moyle G, Gazzard B, Boffito M. Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):675-6.
Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies
Boffito M, Maitland D, Pozniak A. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. J Clin Pharmacol. 2006 Feb;46(2):130-9.
Host determinants of antiretroviral drug activity.
Boffito M, Winston A, Owen A. Host determinants of antiretroviral drug activity. Curr Opin Infect Dis. 2005 Dec;18(6):543-9.
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, Pozniak A, Cooper DA, Phanuphak P, Lange JM, Ruxrungtham K, Burger DM. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005 Nov;56(5):908-13.
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob Agents Chemother. 2005 Oct;49(10):4386-9.
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting
Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, Marrone R, Boffito M, De Rosa FG, Sinicco A, Di Perri G. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother. 2005 Sep;49(9):3966-9.
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther. 2005;10(4):469-77.
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS
Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS. 2005 Jul 22;19(11):1183-8.
The management of HIV-1 protease inhibitor pharmacokinetic intera
Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother. 2005 Jul;56(1):1-5. Epub 2005 Jun 7.
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther. 2005;10(3):375-92.
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions.
Samarasinghe YP, Boffito M, Di Perri G. Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions. J HIV Ther. 2004 Nov;9(4):79-86.
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother. 2005 Apr;55(4):542-5.
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors
Jackson A, Taylor S, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors.AIDS Rev. 2004 Oct-Dec;6(4):208-17.
The pharmacokinetics of HIV protease inhibitor combinations
Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis. 2005 Feb;18(1):1-7.
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects
Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol. 2005 Jan;59(1):38-42.
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84.
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS. 2004 Jun 18;18(9):1291-7.
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B, Pozniak A. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antivir Ther. 2004 Jun;9(3):423-9.
Unexpected drug interactions and adverse events with antiretroviral drugs
Moyle G, Boffito M. Unexpected drug interactions and adverse events with antiretroviral drugs. Lancet. 2004 Jul 3-9;364(9428):8-10. No abstract available.
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients
Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 Jul;48(7):2388-93.
Can we boost enough without ritonavir?
Boffito M, Moyle GJ. Can we boost enough without ritonavir? AIDS Read. 2004 May;14(5):229-30, 233-5.
Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine
Bonora S, Boffito M, D'Avolio A, Sciandra M, Caci AM, Conta F, Sinicco A, De Rosa FG, Di Perri G. Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. AIDS. 2004 Feb 20;18(3):577-8
Pharmacokinetic considerations for combining 2 protease inhibitors
Boffito M, Moyle GJ. Pharmacokinetic considerations for combining 2 protease inhibitors. AIDS Read. 2004 Mar;14(3):110-2, 115-6.
Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy
Palmieri C, Dhillon T, Thirlwell C, Newsom-Davis T, Young AM, Nelson M, Gazzard BG, Bower M. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med. 2006 Jul;7(5):291-3.
Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality
Stebbing J, Bower M, Mandalia S, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol. 2006 Aug;145(2):271-6.
No change to HIV-1 latency with valproate therapy.
Steel A, Clark S, Teo I, Shaunak S, Nelson M, Gazzard B, Kelleher P. No change to HIV-1 latency with valproate therapy. AIDS. 2006 Aug 1;20(12):1681-2.
Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity
Pollock K, Stebbing J, Bower M, Gazzard B, Nelson M. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity. J Antimicrob Chemother. 2006 Jul;58(1):227-8. Epub 2006 May 9.
A single centre cohort experience with a new once daily antiretroviral drug
Stebbing J, Bower M, Holmes P, Gazzard B, Nelson M. A single centre cohort experience with a new once daily antiretroviral drug. Postgrad Med J. 2006 May;82(967):343-6.
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006 May 6;367(9521):1495-502.
The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe
Mazhar D, Stebbing J, Lewis R, Nelson M, Gazzard BG, Bower M. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood. 2006 Apr 15;107(8):3412-4.
Do the mutations M046I and I047A confer resistance to kaletra?
Price H, Jones R, Stevanovic M, Nelson M, Bower M, Mandalia S, Gazzard B. Do the mutations M046I and I047A confer resistance to kaletra? AIDS. 2006 Apr 4;20(6):950-1.
The host control of lytic and latent infection with human herpesvirus-8.
Stebbing J, Gazzard B, Bower M. The host control of lytic and latent infection with human herpesvirus-8. J Infect Dis. 2006 Apr 15;193(8):1051-3. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med. 2006 Apr;7(3):146-55
The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma.
Stebbing J, Mazhar D, Lewis R, Palmieri C, Hatzimichael E, Nelson M, Gazzard B, Bower M. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. Ann Oncol. 2006 Mar;17(3):503-6.
2005
Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study.
Stebbing J, Waters L, Davies L, Mandalia S, Nelson M, Gazzard B, Bower M. Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study. J Clin Oncol. 2005 Nov 1;23(31):8134-6.
Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy
Pires A, Nelson M, Pozniak AL, Fisher M, Gazzard B, Gotch F, Imami N. Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines. 2005 Sep 25;3:7.
Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people
Stebbing J, Sawleshwarkar S, Michailidis C, Jones R, Bower M, Mandalia S, Nelson M, Gazzard B. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad Med J. 2005 Sep;81(959):586-8.
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin
Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):41-6.
Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events.
Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis. 2005 Sep 15;41(6):906-11.
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy
Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005 Aug 16;143(4):265-73.
Stebbing J. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.
Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol. 2005 Aug 1;23(22):5224-8.
The effect of statins on HIV rebound and blips
Waters L, Stebbing J, Jones R, Mandalia S, Bower M, Stefanovic M, Nelson M, Gazzard B. The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):637-8.
Human BDCA-1-positive blood dendritic cells differentiate into phenotypically distinct immature and mature populations in the absence of exogenous maturational stimuli: differentiation failure in HIV infection
Patterson S, Donaghy H, Amjadi P, Gazzard B, Gotch F, Kelleher P. Human BDCA-1-positive blood dendritic cells differentiate into phenotypically distinct immature and mature populations in the absence of exogenous maturational stimuli: differentiation failure in HIV infection. J Immunol. 2005 Jun 15;174(12):8200-9.